The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 4:33 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #68. Mallinckrodt plc Cadence Pharmaceuticals, Inc.

Acquirer: Mallinckrodt plc (MNK)
Acquiree: Cadence Pharmaceuticals, Inc. (CADX)
Details: Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. As previously disclosed, Mallinckrodt expects that the acquisition will be immediately accretive to its fiscal year 2014 adjusted diluted earnings per share, and significantly accretive to its fiscal year 2015 adjusted diluted earnings per share.

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.

MNK SEC Filing Email Alerts Service


Open the MNK Page at The Online Investor »

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.

MNK SEC Filing Email Alerts Service


Open the CADX Page at The Online Investor »

Company Name: 
Mallinckrodt Plc
Stock buyback: 
MNK buyback
Website: 
www.mallinckrodt.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MNK: 
51
Total Market Value Held by ETFs: 
$72.31M
Total Market Capitalization: 
$390.00M
% of Market Cap. Held by ETFs: 
18.54%
Company Name: 
Cadence Pharmaceuticals Inc
Website: 
www.cadencepharm.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes


Healthcare M&A - Slide 68 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.